MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Acquires 11,899 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock in a transaction on Thursday, August 20th. The shares were purchased at an average cost of $1.37 per share, with a total value of $16,301.63. Following the acquisition, the director directly owned 600,117 shares of the company’s stock, valued at approximately $822,160.29. The trade was a 2.02% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

MAIA Biotechnology Price Performance

NYSEAMERICAN MAIA opened at $1.35 on Tuesday. The stock’s 50 day simple moving average is $1.37 and its 200-day simple moving average is $1.46. The company has a market cap of $82.12 million, a PE ratio of -2.18 and a beta of 0.24. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the business. Solas Capital Management LLC purchased a new stake in MAIA Biotechnology during the 2nd quarter valued at about $4,364,000. Centric Wealth Management purchased a new position in MAIA Biotechnology in the 2nd quarter worth approximately $1,107,000. Cable Car Capital LP acquired a new position in shares of MAIA Biotechnology during the 2nd quarter worth approximately $741,000. BlackRock Inc. acquired a new position in shares of MAIA Biotechnology during the 2nd quarter worth approximately $580,000. Finally, Geode Capital Management LLC grew its position in shares of MAIA Biotechnology by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after purchasing an additional 25,684 shares in the last quarter. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.